Johnson & Johnson (JNJ) Acquisitions (2009 - 2025)
Johnson & Johnson's (JNJ) quarterly Acquisitions came in at $3.0 billion in Q4 2025, up 304000.0% year-on-year from N/an in Q4 2024, and up 304000.0% quarter-over-quarter from $1.0 million in Q3 2025.
Johnson & Johnson (JNJ) Acquisitions (2009 - 2025) Analysis & Trends
Johnson & Johnson has disclosed Acquisitions across 17 years of filings, most recently posting $3.0 billion for Q4 2025.
- Acquisitions for Q4 2025 came in at $3.0 billion, up 304000.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.5 billion (up 223.36% YoY), and the FY2025 annual result was $17.5 billion, up 15.54% from the prior year.
- Acquisitions came in at $3.0 billion for Q4 2025 at Johnson & Johnson, up from $1.0 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $17.7 billion in Q1 2023 to a low of $1.0 million in Q4 2024.
- The 5-year median for Acquisitions is $1.8 billion (2024), against an average of $4.5 billion.
- Across the five-year window, Acquisitions tumbled 99.95% in 2024 and jumped 304000.0% in 2025, its largest moves.
- Johnson & Johnson's Acquisitions stood at $6.4 billion in 2021, then sank by 96.05% to $252.0 million in 2022, then surged by 653.97% to $1.9 billion in 2023, then sank by 99.95% to $1.0 million in 2024, then surged by 304000.0% to $3.0 billion in 2025.
- The last three Acquisitions figures came in at $3.0 billion (Q4 2025), $1.0 million (Q3 2025), and $14.5 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 65.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 28, 2025 | 3.04 Bn |
| Sep 28, 2025 | 1.00 Mn |
| Jun 29, 2025 | 14.46 Bn |
| Dec 29, 2024 | 1.00 Mn |
| Sep 29, 2024 | 1.80 Bn |
| Jun 30, 2024 | 1.80 Bn |
| Mar 31, 2024 | 1.81 Bn |
| Dec 31, 2023 | 1.90 Bn |
| Jan 1, 2023 | 17.65 Bn |
| Apr 3, 2022 | 252.00 Mn |
| Jan 3, 2021 | 6.37 Bn |
| Jun 28, 2020 | 800.00 Mn |
| Mar 29, 2020 | 939.00 Mn |
| Dec 29, 2019 | 4.90 Bn |
| Sep 29, 2019 | 216.00 Mn |
| Jun 30, 2019 | 3.40 Bn |
| Mar 31, 2019 | 1.68 Bn |
| Sep 30, 2018 | 675.00 Mn |
| Jul 1, 2018 | 140.00 Mn |
| Apr 1, 2018 | 82.00 Mn |